The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Allergy Therapeutics plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Allergy Therapeutics plc and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- Allergy Therapeutics plc - Brief Allergy Therapeutics plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Allergy Therapeutics plc human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Allergy Therapeutics plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Allergy Therapeutics plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Allergy Therapeutics plc’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of Allergy Therapeutics plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Allergy Therapeutics plc’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Allergy Therapeutics plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Allergy Therapeutics plc and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 4
Allergy Therapeutics plc Snapshot 5
Allergy Therapeutics plc Overview 5
Key Information 5
Key Facts 5
Allergy Therapeutics plc - Research and Development Overview 6
Key Therapeutic Areas 6
Allergy Therapeutics plc - Pipeline Review 8
Pipeline Products by Stage of Development 8
Allergy Therapeutics plc - Pipeline Products Glance 9
Allergy Therapeutics plc - Late Stage Pipeline 9
Registration Filed Products/Combination Treatment Modalities 9
Phase III Products/Combination Treatment Modalities 10
Allergy Therapeutics plc Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Allergy Therapeutics plc-Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Allergy Therapeutics plc - Drug Profiles 14
Pollinex Quattro Grass 14
Pollinex Quattro Japanese Cedar 15
Pollinex Quattro Ragweed 16
Pollinex Quattro Tree 18
Sublingual MPL 19
Allergy Therapeutics plc - Pipeline Analysis 20
Allergy Therapeutics plc - Pipeline Products by Therapeutic Class 20
Allergy Therapeutics plc - Pipeline Products by Route of Administration 21
Allergy Therapeutics plc - Dormant Projects 22
Allergy Therapeutics plc - Firms Statement 23
Allergy Therapeutics plc - Operations and Subsidiaries 24
Head Office 24
Other Locations and Subsidiaries 24
Recent Developments 26
April 28, 2006: Allergy Therapeutics Announces Positive Outcome For Its Key Clinical Efficacy And Safety Study Of Pollinex Quattro Ragweed 26
April 26, 2011: FDA To Lift Allergy Therapeutics INDs Clinical Hold For Three MATA-MPL Products 26
October 23, 2001: Allergy Presents Draft Report Of A Phase IIb Clinical Trial For Pollinex Quattro Tree Pollen Vaccine 27
July 23, 2009: Allergy Therapeutics Announces Granting Of European Patent For MPL-Based Sublingual Vaccines 27
July 23, 2009: European Patent Granted For MPL-Based Sublingual Vaccines 28
January 23, 2007: Allergy Therapeutics Announces Commencement Of Pollinex Quattro Grass Dosing In Phase III Trials 28
September 22, 2008: Allergy Therapeutics plc Announces Positive Results From Its Pollinex Quattro Ragweed Phase III Study 29
June 21, 2006: Allergy Therapeutics Announces Clinical Trial - R205 Update For Pollinex Quattro Ragweed 29
July 19, 2006: Allergy Therapeutics Announces Successful Review Meeting With Japan’s Pharmaceutical And Medical Devices Agency Japan For The Development Of Pollinex Quattro 30
June 14, 2007: Allergy Therapeutics Announces Initiation Of Pollinex Quattro Grass Phase III Trial 31
May 14, 2008: Allergy Therapeutics Announces Phase III Trial Result Of Pollinex Quattro Grass 31
May 14, 2008: Pivotal Phase III Pollinex Quattro grass study meets primary efficacy endpoint 32
October 13, 2006: Allergy Therapeutics Announces Completion Of Phase II Clinical Trials Of Pollinex Quattro Ragweed 32
June 08, 2011: Allergy Therapeutics Receives Report On March keting Authorization Application For Pollinex Quattro From Paul Ehrlich Institute 33
June 07, 2010: New Efficacy Data Emphasize The Benefit Of Pollinex Quattro Grass 34
May 04, 2009: Allergy Therapeutics Announces Submission Of Pollinex Quattro Grass Dossier For European Union ('EU') Regulatory Review 34
December 03, 2004: Allergy Therapeutics Granted UK Patent For Sublingual Vaccine 35
April 02, 2007: Allergy Therapeutics plc Announces Initiation Of Pivotal Phase III Pollinex Quattro Ragweed Allergy Trial 35
Financial Deals Landscape 36
Allergy Therapeutics plc, Merger and Acquisition Deal Summary 36
Allergy Therapeutics plc, Pharmaceuticals and Healthcare, Merger and Acquisition Deal Details 37
Partnerships 37
Allergy Therapeutics Enters Into Distribution Agreement With Lincoln Medical 37
Allergy Therapeutics Enters Into Distribution Agreement With Nycomed Canada 38
Allergy Therapeutics Enters Into Agreement With Allerpharma 39
Equity Offering 40
Allergy Therapeutics Completes Private Placement Of US$ 3.36 Mln 40
Allergy Therapeutics Completes Private Placement of US$ 39 Mln 42
Allergy Therapeutics Completes Private Placement Of US$ 33 Mln 44
Allergy Therapeutics Completes Private Placement Of US$ 27 Mln 46
Allergy Therapeutics Completes Initial Public Offering Of US$ 28.8 Mln 48
Acquisition 50
Allergy Therapeutics Completes Acquisition Of Teomed 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 53
Contact Us 53
Disclaimer 53

List of Tables

Allergy Therapeutics plc - Pipeline by Therapy Area and Indication, H2 2011 7
Allergy Therapeutics plc - Pipeline by Stage of Development, H2 2011 8
Allergy Therapeutics plc - Filed, H2 2011 9
Allergy Therapeutics plc - Phase III, H2 2011 10
Allergy Therapeutics plc - Phase II, H2 2011 11
Allergy Therapeutics plc - Phase I, H2 2011 12
Allergy Therapeutics plc - Pipeline By Therapeutic Class, H2 2011 20
Allergy Therapeutics plc - Pipeline By Route of Administration, H2 2011 21
Allergy Therapeutics plc - Dormant Developmental Projects, 2010 22
Allergy Therapeutics plc, Subsidiaries 24
Allergy Therapeutics plc, Merger and Acquisition Deal Summary 36
Allergy Therapeutics Enters Into Distribution Agreement With Lincoln Medical 37
Allergy Therapeutics Enters Into Distribution Agreement With Nycomed Canada 38
Allergy Therapeutics Enters Into Agreement With Allerpharma 39
Allergy Therapeutics Completes Private Placement Of US$ 3.36 Mln 40
Allergy Therapeutics Completes Private Placement of US$ 39 Mln 42
Allergy Therapeutics Completes Private Placement Of US$ 33 Mln 44
Allergy Therapeutics Completes Private Placement Of US$ 27 Mln 46
Allergy Therapeutics Completes Initial Public Offering Of US$ 28.8 Mln 48
Allergy Therapeutics Completes Acquisition Of Teomed 50

List of Figures

Allergy Therapeutics plc - Pipeline by Therapy Area and Indication, H2 2011 7
Allergy Therapeutics plc - Pipeline by Stage of Development, H2 2011 8
Allergy Therapeutics plc - Pipeline By Therapeutic Class, H2 2011 20
Allergy Therapeutics plc - Pipeline By Route of Administration, H2 2011 21

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.